UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Position in XERS — Xeris Biopharma Holdings, Inc.
CIK 861177
NEW YORK, NY
Position in XERS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$3,874,827
-$1,239,015 QoQ
Shares Held
668,074
+2.6% QoQ
Ownership
0.387%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 73.65516394890386.ToString("F0")%
Shared 0.ToString("F0")%
None 26.344836051096138.ToString("F0")%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $926,551,772 across 34 Drug Manufacturers - Specialty & Generic names. XERS ranks #14 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
4,398,351 | $519,929,066 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
207,309 | $122,930,085 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
571,719 | $75,318,257 | |
| 4 | VTRS |
Viatris Inc
|
3,964,630 | $53,562,146 | |
| 5 | LNTH |
Lantheus Holdings, Inc.
|
486,498 | $36,900,870 | |
| 6 | ELAN |
Elanco Animal Health Inc
|
1,526,922 | $36,539,240 | |
| 7 | ALKS |
Alkermes plc.
|
403,153 | $14,255,486 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
443,527 | $9,207,616 |
All Filings in XERS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,874,827 | 668,074 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $5,113,842 | 651,445 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $1,493,356 | 183,459 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $175,680 | 37,619 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||